Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia after Same-Day Dosing of Eflapegrastim in Patients with Breast Cancer Receiving Docetaxel and Cyclophosphamide (NCT04187898)

Lee S. Schwartzberg, MD, Jawad Francis, MD, Hlalah Osama, MD, Manuel Modiano, MD, Jayaram Bharadwaj, MD, Shanta Chawla, MD, Gajanan Bhat, PhD, Francois Lebel, MD FRCPC, Nishan Tchekmedyian, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134012

Published: 2020

Journal Articles

Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States

Scott F. Huntington, MD MPH, Pamela R. Soulos, Paul M. Barr, MD, Ryan Jacobs, MD, Frederick Lansigan, MD, Oreofe O. Odejide, MD MPH, Lee S. Schwartzberg, MD, Amy J. Davidoff, PhD MS, Cary P Gross, MD

Blood (2019) 134 (Supplement_1): 797.

https://doi.org/10.1182/blood-2019-122054

Published: 2019

Journal Articles

Chemotherapy-Induced Nausea and Vomiting (CINV) in Hematologic Malignancy Patients Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC)

Lee S. Schwartzberg, MD FACP, Eric J. Roeland, MD, Paul J.E. Miller, PhD, Mark S. Walker, PhD

Blood (2016) 128 (22): 2410.

https://doi.org/10.1182/blood.V128.22.2410.2410

Published: 2016

Journal Articles

Likelihood of a Subsequent Chemotherapy Induced Nausea and Vomiting Event In Patients with Hematologic Malignancies Receiving Chemotherapy.

Bruce Feinberg, DO, Lee S. Schwartzberg, MD, FACP, James Gilmore, PharmD, Sally Haislip, RPh, James Jackson, PharmD, MPH, Gagan Jain, PhD, Sanjeev Balu, PhD, MBA, Deborah Buchner, PhD

Blood (2010) 116 (21): 3819.

https://doi.org/10.1182/blood.V116.21.3819.3819

Published: 2010

Journal Articles

Reported Bone Pain in Cancer Patients Receiving Chemotherapy in Pegfilgrastim Clinical Trials: A Retrospective Analysis.

Stephanie A. Gregory, MD, May Mo, PhD, Charles Vogel, MD, FACP, Jorge Sierra, MD, PhD, Lee S. Schwartzberg, MD, FACP

Blood (2009) 114 (22): 4561.

https://doi.org/10.1182/blood.V114.22.4561.4561

Published: 2009

Journal Articles

Symptom Burden in Patients with Follicular Lymphoma Undergoing Maintenance Treatment with Rituxan Compared with Observation.

Mark Walker, PhD, Edward Stepanski, PhD, Carolina Reyes, PhD, Murad Hasan, MD, DrPH, Lee S. Schwartzberg, MD

Blood (2009) 114 (22): 2498.

https://doi.org/10.1182/blood.V114.22.2498.2498

Published: 2009

Journal Articles

Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin’s Lymphoma.

Richard H. Van der Jagt, MD, Philip Cohen, MD, Bruce D. Cheson, MD, Anil Tulpule, MD, Jordan A. Herst, MD,FRCP, Bernard Lemieux, MD, Lee S. Schwartzberg, MD, Katherine Sue Robinson, MD, Jennifer W. Oliver, MD, Michael E. Williams, MD

Blood (2006) 108 (11): 2710.

https://doi.org/10.1182/blood.V108.11.2710.2710

Published: 2006

Journal Articles

Bendamustine HCl (TREANDA TM ) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).

Katherine Sue Robinson, MD, Michael E. Williams, MD, Philip Cohen, MD, Anil Tulpule, MD, Richard H. van der Jagt, MD, Jordan A. Herst, MD, Robin M. Joyce, MD, Alberto Bessudo, MD, Bernard Lemieux, MD, Lee S. Schwartzberg, MD, Jennifer Oliver, MD, Ely Benaim, MD

Blood (2005) 106 (11): 923.

https://doi.org/10.1182/blood.V106.11.923.923

Published: 2005

Journal Articles

Clinical Significance of Symptom Burden and Quality of Life Decrement in Cancer Patients with Mild Anemia.

Lee S. Schwartzberg, MD, Barry V. Fortner, PhD, Arthur C. Houts, PhD

Blood (2004) 104 (11): 5305.

https://doi.org/10.1182/blood.V104.11.5305.5305

Published: 2004

NARROW

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia after Same-Day Dosing of Eflapegrastim in Patients with Breast Cancer Receiving Docetaxel and Cyclophosphamide (NCT04187898)

Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States

Chemotherapy-Induced Nausea and Vomiting (CINV) in Hematologic Malignancy Patients Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC)

Likelihood of a Subsequent Chemotherapy Induced Nausea and Vomiting Event In Patients with Hematologic Malignancies Receiving Chemotherapy.

Reported Bone Pain in Cancer Patients Receiving Chemotherapy in Pegfilgrastim Clinical Trials: A Retrospective Analysis.

Symptom Burden in Patients with Follicular Lymphoma Undergoing Maintenance Treatment with Rituxan Compared with Observation.

Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin’s Lymphoma.

Bendamustine HCl (TREANDA TM ) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).

Clinical Significance of Symptom Burden and Quality of Life Decrement in Cancer Patients with Mild Anemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only